INO Therapeutics
M&A
STATUS
401-500
EMPLOYEES
IPO
LATEST DEAL TYPE
(Cancelled)
2
FINANCING ROUNDS
Description
Manufacturer of late stage drugs for the treatment of heart and lung functions. The company's primary offering INOmax is used to carry oxygenated blood to the body tissues, and for the treatment of persistant pulmonary hypertension in the newborn.
Website
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Office
- Six State Route 173
- Clinton, NJ 08809
- United States
+1 (908) 000-0000
INO Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore INO Therapeutics‘s full profile, request access.
Request full access to PitchBookINO Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore INO Therapeutics‘s full profile, request access.
Request full access to PitchBook